Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trial

Fig. 1

Structure of Markov model to assess cost-effectiveness of pralatrexate in treating R/R PTCL. (a) corresponds to state-transition diagram and (b) corresponds to decision tree. CC, conventional chemotherapy; CR, complete response; PD, progressive disease; PR, partial response; PTCL, peripheral T-cell lymphoma; R/R, relapsed or refractory; SCT, stem cell transplantation; SD, stable disease.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us